transcatheter aortic valve replacement

PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients

Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with severe symptomatic aortic stenosis. For those that can be accessedfemorally, TAVI seems even better than surgery. In all, 2032 intermediate risk patients were randomized in 57 centers to TAVI with Sapien<a href="https://solaci.org/en/2016/04/08/partner-2a-tavi-not-inferior-to-surgery-in-intermediate-risk-patients/" title="Read more" >...</a>

SAPIENS 3: Favorable outcomes with TAVI in intermediate risk patients

Transcatheter aortic valve replacement is a safe and effective alternative to surgery in patients with severe aortic stenosis and high surgical risk as the 5-year results of PARTNER 1 Alternate showed. The aim of this study was to evaluate the result of the Edwards Sapien 3 valve in patients with severe aortic stenosis and intermediate<a href="https://solaci.org/en/2015/06/24/sapiens-3-favorable-outcomes-with-tavi-in-intermediate-risk-patients/" title="Read more" >...</a>

TAVR é um procedimento tão seguro e eficaz quanto a substituição cirúrgica num seguimento de dois anos em pacientes de menor risco.

Fundamentos e &nbsp;Objetivos: A substitui&ccedil;&atilde;o da v&aacute;lvula a&oacute;rtica via transcateter (TAVR) &eacute; uma op&ccedil;&atilde;o em determinados pacientes cir&uacute;rgicos de alto risco com estenose da v&aacute;lvula a&oacute;rtica grave. Desconhecemos se a TAVR pode ser introduzida com seguran&ccedil;a para os pacientes de baixo risco. O estudo NOTION (Nordic Aortic Valve Intervention Trial) &eacute; um ensaio cl&iacute;nico randomizado<a href="https://solaci.org/en/2015/06/24/tavr-e-um-procedimento-tao-seguro-e-eficaz-quanto-a-substituicao-cirurgica-num-seguimento-de-dois-anos-em-pacientes-de-menor-risco-2/" title="Read more" >...</a>

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic<a href="https://solaci.org/en/2015/06/24/partner-cohort-a-at-three-years-the-benefit-continues/" title="Read more" >...</a>

PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.

In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis balloon-expandable Edwards-SAPIEN showed a mortality reduction compared with standard treatment. However, the Edwards SAPIEN device is associated with peri-procedural complications. The new generation of Edwards SAPIEN XT prosthesis incorporates significant improvements in the profile of the delivery system,<a href="https://solaci.org/en/2015/06/24/partner-2-edwards-sapien-xt-is-even-better-results-for-partner-ii-cohort-b/" title="Read more" >...</a>

TAVR minimally invasive, shorter hospital stay and costs without compromising safety or efficacy

Original title:&nbsp;Comparison of Transfemoral TranscatheterAortic Valve Replacement Performedin the Catheterization Laboratory(Minimalist Approach) Versus HybridOperating Room (Standard Approach). Outcomes and CostAnalysis.&nbsp;Reference:&nbsp;VasilisBabaliaros et al. J Am CollCardiolIntv 2014;7:898&ndash;904. This retrospective study of a center analyzed the results of percutaneous aortic valve replacement (TAVR) performed with a minimally invasive technique that included the closure of the femoral access<a href="https://solaci.org/en/2014/08/25/tavr-minimally-invasive-shorter-hospital-stay-and-costs-without-compromising-safety-or-efficacy/" title="Read more" >...</a>

Looking for the best anti-aggregation scheme after TAVI

Original title:&nbsp;Comparison of Two Antiplatelet Therapy Strategies in Patients Undergoing Transcatheter Aortic Valve Implantation.&nbsp;Reference: Eric Durand et al. Am J Cardiol 2013, et al. Percutaneous aortic valve replacement has been shown to be superior to medical treatment in inoperable patients and not inferior to surgery in high-risk patients. Anti-platelet therapy in these patients is usually<a href="https://solaci.org/en/2013/11/08/looking-for-the-best-anti-aggregation-scheme-after-tavi/" title="Read more" >...</a>

The largest series of post TAVI coronary occlusion published

Original title:&nbsp;Predictive Factors, Management and Clinical Outcomes of Coronary obstruction Following Transcatheter Aortic Valve Implantation Insight From a Large Multicenter Registry&nbsp;Reference:&nbsp;Henrique B. Ribeiro, et; al. J Am Coll Cardiology 2013;62:1552-62 Percutaneous implantation of the aortic valve is a valid strategy in high-risk surgical patients. One of the possible complications of this procedure is the occlusion<a href="https://solaci.org/en/2013/10/29/the-largest-series-of-post-tavi-coronary-occlusion-published/" title="Read more" >...</a>

Prosthetic endocarditis after TAVI, rare and difficult to diagnose

Original title:&nbsp;Prosthetic valve endocarditis after transcatheter aortic valve implantation: the incidence in a single-centre cohort and reflections on clinical, echocardiographic and prognostic features.&nbsp;Reference:&nbsp;Miriam Puls et al. EuroIntervention 2013;8:1407-1418. Prosthetic valve endocarditis is a serious complication of surgical valve replacement and occurs in 0.3 to 1.2% of patients per year. It is basically divided in early<a href="https://solaci.org/en/2013/05/15/prosthetic-endocarditis-after-tavi-rare-and-difficult-to-diagnose/" title="Read more" >...</a>

Post TAVI Hypertension is a predictor of better evolution

Original title:&nbsp;Post-Procedural Hypertension Following Transcatheter Aortic Valve Implantation Incidence and Clinical Significance.&nbsp;Reference:&nbsp;Gidon Y. Perlman et al. J Am Coll Cardiol Intv 2013. Article in press. Pre-procedural hypertension (HTN) is a risk factor and a predictor of increased mortality after surgical aortic valve replacement (AVR). The disappearance of the pressure gradient across the aortic valve following<a href="https://solaci.org/en/2013/05/02/post-tavi-hypertension-is-a-predictor-of-better-evolution/" title="Read more" >...</a>

Top